Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 5, 2003, Pages 417-423

  Thompson, Patrick ^a   Balis, Frank ^b   Serabe, Baruti M ^a,f   Berg, Stacey ^a   Adamson, Peter ^b,g   Klenke, Renee ^a   Aiken, Alberta ^b   Packer, Roger ^c   Murry, Daryl J ^a,h   Jakacki, Regina ^d,i   Blaney, Susan M ^a,e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d RILEY HOSPITAL FOR CHILDREN   (United States)

^e TEXAS CHILDREN S CANCER CENTER   (United States)

^f SANFORD RESEARCH   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Pediatric; Pharmacokinetic; Phenylacetate; Phenylacetylglutamine

Indexed keywords

ANTINEOPLASTON AS2-1; GLUTAMINE DERIVATIVE; PHENYLACETIC ACID; PHENYLACETIC ACID DERIVATIVE; PHENYLACETYLGLUTAMINE; PHENYLALANINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEAMINATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIVIDUALIZATION; METABOLITE; MICHAELIS CONSTANT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR DIFFERENTIATION; ULTRAVIOLET RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTAMINE; HALF-LIFE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; NEOPLASMS; PHENYLACETATES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0242361058     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0674-0     Document Type: Article

References (16)

1. Sandler M, Ruthven CRJ, Goodwin BL, Lee A, Stern GM (1982) Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentration values. J Neurol Neurosurg Psychol 45:366-368
2. Ram Z, Samid D, Walbridge S, Oshiro E, Viola J, Tao-Cheng J-H, Shack S, Thibault A, Myers C, Oldfield E (1994) Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 54:2923-2937
3. Samid D, Shack S, Sherman L (1992) Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 52:1988-1992
4. Samid D, Shack S, Myers C (1993) Selective growth arrest and maturation of prostate cancer cells in vitro by nontoxic, pharmacological concentrations of phenylacetate. J Clin Invest 91:2288-2295
5. Samid D, Ram Z, Hudgins W, Shack S, Liu L, Walbridge S, Oldfield E, Myers C (1994) Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 54:891-895
6. Samid D, Yeh A, Prasanna P (1992) Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 80:1576-1581
7. Liu L, Shack S, Stetler-Stevenson W, Hudgins W, Samid D (1994) Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Dermatol 103:335-340
8. Sidell N, Wada R, Han G, Chang B, Shack S, Moore T, Samid D (1995) Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int J Cancer 60:507-514
9. Brusilow S, Danney M, Waber L, Batshaw M, Burton B, Levitsky L, Roth K, Mckeethren C, Ward J (1984) Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310:1630-1634
10. Simell O, Sipila I, Rajante J, Valle D, Brusilow S (1986) Waste nitrogen excretion via amino acid acetylation: benzoate and phenylacetate in lysinuric protein intolerance. Pediatr Res 20:1117-1121
11. Moldave K, Meister A (1957) Synthesis of phenylacetylglutamine by human tissue. J Biol Chem 229:463-476
12. James J, Smith R, Williams F, Reidenberg M (1972) The conjugation of phenylacetic acid in man, sub-human primates and non-primate species. Proc R Soc Lond B 182:25-35
13. Thibault A, Cooper M, Figg W, Venzon D, Sartor A, Tompkins A, Weinberger M, Headlee D, McCall N, Samid D, Myers C (1994) A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54:1690-1694
14. Thibault A, Samid D, Cooper M, Figg W, Tompkins A, Patronas N, Headlee D, Kohler D, Venzon D, Myers C (1995) Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75:2932-2938
15. National Cancer Institute (1988) Guidelines for reporting of adverse drug reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda, MD
16. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175